Brief: SynAct Pharma Says Advance Analysis Supports Phase 3 Development
07/09/2026 10:14
BRIEF-SynAct Pharma Says Advance Analysis Supports Phase 3 Development Sept 7 (Reuters) - SynAct Pharma AB SYNACT.ST:
FURTHER ANALYSIS OF PHASE 2B ADVANCE STUDY REINFORCES PHASE 2B EXPAND RESULTS AND SUPPORTS PHASE 3 DEVELOPMENT
FDA DISCUSSIONS ON TRIAL DESIGN PLANNED FOR Q4 2026
Source text: ID:nMFN48H78F
Further company coverage: SYNACT.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on SynAct Pharma AB
See all newsSweden's SynAct Pharma Q3 net loss narrows as expenses fall
Brief: SynAct Pharma Q3 Net Income SEK -32.177 Million
Brief: SynAct Pharma Signs First Commercial Partnership For Resomelagon
Brief: WHO Names Resomelagon Among Key Dengue Drug Candidates
Brief: SynAct Pharma Says Advance Analysis Supports Phase 3 Development